Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eli Lilly's Oncology Drug Is First Candidate For Australia's New Provisional Approval Pathway

Executive Summary

Australia gets the ball rolling on its new pathway for provisional approval of innovative prescription medicines. 

You may also be interested in...



Merck Scores A First With Keytruda Under Australia's Provisional Pathway

The Therapeutic Goods Administration has provisionally approved new uses of the anticancer medicine based on early clinical data. 

Increased Fees For Pharma Imminent In Australia

From July 1, pharmaceutical companies will pay higher fees to Australia’s Therapeutic Goods Administration.

Eligibility Decisions Near For Australia’s New Provisional Pathway

The first registration of a medicine under Australia’s new provisional approval pathway could take place at the end of this year, according to plans by the Therapeutic Goods Administration.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel